Valued at USD 6.51 billion in 2025, the global AI in oncology market is projected to reach USD 8.26 billion in 2026 and USD 56.44 billion by 2034, growing at a CAGR of 27.1% during the forecast period 2026–2034. Precision medicine and early cancer detection capabilities are key growth drivers. Major players include Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies, and PathAI. This article examines the component, cancer type, and treatment segments shaping demand.

AI in Oncology Market Scope and Segmentation

The AI in oncology market is growing due to technological advancements and the integration of AI in applications such as classification, detection, characterization, and monitoring. Investments by government and private entities are improving diagnostic and therapeutic capabilities. The market is segmented by component into software solutions, hardware, and services; by cancer type across breast cancer, lung cancer, prostate cancer, colorectal cancer, and others; and by treatment type across chemotherapy, radiotherapy, and others. Precision medicine, early detection capabilities, and public and private R&D investment are expected to contribute significantly to growth.

Software Solutions Dominate Component Revenue

Software solutions led the AI in oncology market with a 71.5% share in 2025, fueled by growing use of AI-powered software for cancer diagnosis, treatment planning, and medical imaging analysis. Entrepreneurial start-ups are also contributing. MedCognetics obtained FDA approval in December 2022 for QmTRIAGE, an AI-enabled platform for breast cancer screening that is anticipated to reduce the cost and time associated with imaging while improving outcomes. Market players are also developing innovative solutions to broaden accessibility to a larger population.

Breast Cancer Segment Holds the Largest Share

The breast cancer segment held the largest share of 31.9% in 2025, supported by rising global prevalence and growing adoption of AI-assisted screening and diagnosis. The report cites American Society of Clinical Oncology figures, including an estimated 297,790 new breast cancer cases in 2023, underscoring the incidence that drives demand for advanced technological products. Rising cancer prevalence and shortages of healthcare professionals are accelerating AI adoption for efficient, accurate diagnosis.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/ai-in-oncology-market

Chemotherapy Personalization Through AI

The chemotherapy segment accounted for the largest treatment share of 36.7% in 2025. AI supports healthcare professionals in building personalized digital profiles for patients, enabling dosage customization during treatment, optimizing drug selection, and minimizing dosage-related side effects. The American Cancer Society estimates that about 60% of Stage 4 bladder cancer patients undergo chemotherapy, illustrating the scale of this treatment modality. Ongoing research on integrating AI into chemotherapy supports growth, including regimens customized with reduced dosage and fewer side effects.

Precision Oncology and Early Cancer Detection

Growing demand for early cancer detection and diagnosis is propelling adoption of AI-powered imaging and diagnostic solutions, while rising use of AI for personalized treatment planning fuels precision oncology. In March 2023, Qritive introduced QAi Prostate, an AI-powered tool that helps identify prostatic adenocarcinoma regions and classify benign and malignant tumors in biopsy samples. Restraints include data privacy concerns, regulatory challenges, and limited access to high-quality clinical datasets. Looking ahead, AI integration is expected to improve patient monitoring, prognosis, and treatment outcomes.

Regional Landscape and Competitive Insights

North America dominated with a 42.8% revenue share in 2025, backed by established digital healthcare infrastructure, favorable reimbursement policies, and a strong presence of AI technology and oncology solution providers. Asia Pacific is projected to register the highest CAGR of 32.4%, attributed to rising digitalization of diagnostic laboratories and hospitals, increasing cancer prevalence, and expanding investment. Globocan data for 2020 cites approximately 19 million new cancer cases globally, with Asia-Pacific contributing 9.7 million.

Outlook for the AI in Oncology Market

Rising integration of AI in oncology and personalized cancer treatment is expected to sustain strong growth through 2034. Deep learning, machine learning, and cloud-based oncology platforms are expected to widen access and strengthen clinical decision-making.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market